NASDAQ : LPCN
Lipocine Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.44 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.87M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 11.87M |
| Enterprise Value | -11.14M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 8.24M |
| Shares Outstanding | 8.24M |
| Shares Change (YoY) | +22.05% |
| Shares Change (QoQ) | +20.93% |
| Owned by Insiders (%) | 4.98% |
| Owned by Institutions (%) | 20.29% |
| Float | 6.51M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.56 |
| Forward PS | 22.74 |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.48 |
| Quick Ratio | 11.39 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -60.94% |
| Return on Assets (ROA) | -37.04% |
| Return on Invested Capital (ROIC) | -39.87% |
| Return on Capital Employed (ROCE) | -57.74% |
| Weighted Average Cost of Capital (WACC) | 6.32% |
| Revenue Per Employee | $112,104 |
| Profits Per Employee | -$846,529 |
| Employee Count | 14 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 200 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -46.47% |
| 50-Day Moving Average | 1.99 |
| 200-Day Moving Average | 3.91 |
| Relative Strength Index (RSI) | 30.93 |
| Average Volume (20 Days) | 5,683,548 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 351,433 |
| Short Previous Month | 97,816 |
| Short % of Shares Out | 4.26% |
| Short % of Float | 5.39% |
| Short Ratio (days to cover) | 0.07 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.57M |
| Gross Profit | 1.57M |
| Operating Income | -12.57M |
| Pretax Income | -11.85M |
| Net Income | -11.85M |
| EBITDA | -12.51M |
| EBIT | -12.57M |
| Loss Per Share | -$1.82 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 23.27M |
| Total Debt | 257,807 |
| Net Cash | 23.01M |
| Net Cash Per Share | $2.79 |
| Equity (Book Value) | 21.77M |
| Book Value Per Share | 2.64 |
| Working Capital | 21.67M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -11.19M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 58,566 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.19M |
| FCF Per Share | -$1.36 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -800.82% |
| Pretax Margin | -755.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.05% |
| Shareholder Yield | -22.05% |
| Earnings Yield | -126.25% |
| FCF Yield | -94.26% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.00 |
| Price Target Difference | 247.22% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | -15.33% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.64 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |